trial

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

NCTId NCT01493726
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 88 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2013-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
88 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-12
Primary completion
2013-06
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ALKS 9072, Low DoseALKS 9072, Med doseALKS 9072, High Dose

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Alkermes Medical Director, MDStudy Director

Sites

6 total
Atlanta, United StatesHoffman Estates, United StatesSt Louis, United StatesWillingboro, United StatesPhiladelphia, United StatesIrving, United States

Facts & assertions

4 sourced
Enrollment
88
Phase
PHASE1
Primary Completion Date
2013-06
Status
COMPLETED
relationships
The graph out of here
drug
ALKS 9072, Low Dose
drug
ALKS 9072, Med dose
drug
ALKS 9072, High Dose
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alkermes Medical Director, MD
person